BioinfometricsBioinfometrics logo mark — DNA double helix encoded as a financial candlestick chart on an upward trend axis. The dual-read mark simultaneously represents molecular biology and market data intelligence.

Bioinfometrics

Treasury Wants to Fence Off Chinese Biotech. Industry Trials With a Site in China Already Equal 68% of the US Count

A proposed Treasury rule published October 26 would add biotechnology, including bioinformatics tools, to the US ban on certain investments in China. The trial register shows how large the sector it targets has become.

Illustration of two rising stacks of lab plates on either side of a dashed fence line, with an amber gate in the fence
Martin DAVILABy Martin DAVILA11/5/20266

On October 26 the US Treasury published a proposed rule that would, for the first time, put biotechnology on the list of sectors where US investors may not put money into Chinese companies. The rule implements the Comprehensive Outbound Investment National Security (COINS) Act, which Congress passed in December 2025. Congress did not name biotechnology in that law. Treasury added it using the authority the law gives it to designate sectors.

Comments are open until December 7. Before reading what the rule covers, it helps to see how much of drug development now runs through China.

How big is China in clinical development?

We counted interventional trials registered on ClinicalTrials.gov by the year they started and by whether they list at least one site in China or in the United States, keeping only trials led by industry sponsors.

Industry trials starting with a site in China rose 6.5-fold in ten years, from 11% of the US count to 68%.

Industry-sponsored interventional trials on ClinicalTrials.gov, by start year and site country. A trial with sites in both countries counts in both lines.

  1. 12023: China passes half of the US count

Source: ClinicalTrials.gov API v2, queried November 2, 2026. ClinicalTrials.gov is a US register. Many trials run only in China are registered on the Chinese register instead, so the China line is likely an undercount.

View data
yearchinaus
20152632371
20163002250
20174252373
20185792599
20197272500
20208392520
202113002961
202212442769
202314692448
202414812416
202517202526

In 2015, 263 industry trials started with a site in China and 2,371 with a site in the US. In 2025 the counts were 1,720 and 2,526. China grew 6.5 times; the US grew 7%. Counting all sponsors, not only industry, China went from 1,174 starts to 5,083 and the US from 6,762 to 7,954.

This is the activity that US licensing deals draw on. Our M&A analysis covered one example: Novartis licensing an mRNA T-cell engager from China's Abogen for $575 million upfront.

What would the rule prohibit?

The proposal defines "prohibited technology" in biotechnology as using a biological system, or a component of one, to modify, enhance, produce or control five kinds of output: export-controlled agents and toxins, energetic materials, novel functional materials, pharmaceutical compounds and biofuels. The pharmaceutical category is broad. It lists small molecules, vaccines, blood products, cell and gene therapies and antibodies, as well as their delivery systems.

It also lists equipment and software. US persons would be barred from investing in Chinese companies that develop or produce:

  • biological sequencing technology, short-read or long-read;
  • spectral flow cytometers and cell sorters, or those with 26 or more detectors or channels;
  • liquid chromatography mass spectrometers designed for top-down proteomics;
  • computational or bioinformatics tools for the research, design, modelling, discovery or assessment of biological systems;
  • hardware, robotics or software for automated experiments, including cloud labs.

For readers of this blog, the fourth item is the one to notice. Bioinformatics software is named explicitly.

The rule would also cover companies on two government lists: the Defense Department's Section 1260H list of Chinese military companies and the list of biotechnology companies of concern under the BIOSECURE Act. And it adds Russia, Iran, Cuba, North Korea and Venezuela as countries of concern.

Does it stop pharma from licensing Chinese drugs?

As written, the rule targets investments: equity stakes, joint ventures and similar transactions. Reporting by STAT and Fierce Biotech says that buying the rights to a drug invented in China would still be allowed. Law firm alerts, such as Goodwin's, warn that joint ventures and co-development deals could fall inside the rule depending on how they are structured. The proposal also asks for comments on whether "pharmaceutical compounds" should be narrowed to advanced or frontier technologies, so the breadth of that category is still open.

How many deals does Treasury expect?

Fewer than the trial counts might suggest. Treasury's own cost analysis says PitchBook data show about 300 initial and follow-on investments by almost 230 US investors in Chinese companies across all covered sectors from 2023 to 2025, about 100 a year. It then doubles that to 200 a year to allow for deals the data miss. Biotech is only one of six sectors in that figure.

Limits

Trial counts measure clinical activity, not investment, and the rule regulates investment. A trial with sites in many countries counts once for each country it lists, so the two lines overlap. Start dates are entered by sponsors, and the industry flag is based on the lead sponsor only. The licensing carve-out is described by reporters and law firms; we have read the proposed rule's text on prohibited technologies, but whether a given deal is covered depends on definitions that may change before the final rule.

Sources

  1. US Department of the Treasury, Outbound Investment Security Program Regulations, proposed rule, 91 FR 67396, October 26, 2026, docket TREAS-DO-2026-0595: biotechnology definitions, equipment list, listed entities, new countries of concern, PitchBook-based estimate of about 100 transactions a year doubled to 200, comment deadline December 7, 2026.
  2. ClinicalTrials.gov, API v2, queried November 2, 2026: interventional studies by start year and location country, all sponsors and industry lead sponsors.
  3. STAT, Treasury proposes major restrictions to U.S. investment in Chinese biotech sector, October 23, 2026; Fierce Biotech, Treasury sweeps biotech into proposed COINS Act restrictions, but spares Big Pharma's China licensing deals: licensing and co-development reading.
  4. Goodwin, COINS Act proposal takes aim at biotech and AI investment in China, October 28, 2026: "pure licensing-only transactions" are not restricted; joint ventures and licensing that comes with equity may be.
  5. Related: The exit moved: $130 billion of biotech acquisitions and KRAS G12D went from 2 trial starts to 24.

Found this article helpful? Share it with your network!

Recommended Reading

Discussion (0)

Sign in to join the conversation and share your thoughts

No comments yet. Be the first to start the discussion!